Picard Medical Shares Rise Sharply After Better-than-Expected Q2 Revenue
Picard Medical Inc. (AMEX:PMI) shares surged nearly 43.9% in pre-market trading following the release of second-quarter revenue that significantly exceeded Wall Street forecasts, reaching $2.95 million compared to an expected $1.55 million. The strong sales performance came after a period where the stock had been near multi-month lows and overshadowed concerns over a wider-than-expected quarterly loss of $3.05 per share. The company also released an updated investor presentation under Regulation FD, signaling ongoing efforts to engage with capital markets as it works through its NYSE American listing compliance process. The rally in PMI was largely driven by the earnings surprise rather than broader market trends or sector-wide momentum, and no similar moves were observed among comparable small-cap medical device companies. The stock's proximity to a 52-week low amplified investor reactions, with speculative interest likely contributing to the sharp pre-market move. However, investors remain cautious due to continued profitability challenges.
Tickers: $PMI
Topics: financial performance Regulation FD update stock price movement